Sanofi Stays Mum On Genzyme But Near-Term M&A Appears Likely
Executive Summary
Sanofi-Aventis is dangling over a dangerous patent cliff, facing generic competition to Lovenox, Plavix and other top-selling drugs, and the company's solution to scramble back to safer ground could be a significant acquisition
You may also be interested in...
Sanofi-Aventis Offer To Buy Genzyme Seen As Starting Point For Long Negotiation
French pharma's initial offer in the $67 to $70 per share range expected to rise, perhaps into the $80s.
Sandoz Launches Generic Lovenox
Sandoz has a monopoly on the generic enoxaparin market for now, but Teva insists its ANDA is progressing at FDA.
Sanofi Sues FDA, Claiming Agency Exceeded Its Authority In Approving Enoxaparin
Company claims the agency approved the generic although the innovator drug had not been fully characterized, but odds are against a Sanofi win in court.